|
Euroscreen is a private Belgian, preclinical-stage, Drug Discovery and Development Company targeting G-Protein-Coupled-Receptors (GPCRs) to provide first-in-class small molecule drug candidates for therapeutic area of metabolism, inflammation and Women's Health.
Euroscreen has a track-record on multiple innovative and proprietary chemical entities targeting GPCR due to its recognized know-how and expertise with these targets; having achieved in vivo proof of concept and efficacy in multiple preclinical programs. Euroscreen is now advancing programs of its own to clinical trials, and is actively seeking collaborations to advance its pharmaceutical candidates and further supplement its ongoing research and licensing partnerships with companies such as Boehringer-Ingelheim, Grunenthal, HGS, Ortho-McNeil-Janssen Pharmaceuticals Inc., Monogram Biosciences, Novartis and Pfizer.
Euroscreen also offers a broad patent portfolio for targets and screening tools to out-license to companies developing therapeutic drugs acting through targets as CCR5, Chemerin Receptor, GPR43 antagonists, GPR7/8, ORL1-R, FPRL2, P2Y4, P2Y11 and P2Y13.
In addition to pursuing its drug discovery pipeline, Euroscreen also provides GPCR custom testing services around the world which include HTS-screening, lead optimization support, candidate profiling and target deorphanization/characterization through the services of its Euroscreen FAST Business Unit.
|
